Rallybio shares fall 5.25% premarket despite completing dosing of first cohort in RLYB116 study.

Rallybio Corporation fell 5.25% in premarket trading, despite the company announcing the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116. The company's CEO, Stephen Uden, expressed encouragement with the data generated to date, reinforcing confidence in the RLYB116 program.